The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Curcumin, the golden spice in treating cardiovascular diseases
Abstract
Cardiovascular diseases (CVDs) cause the largest mortality worldwide, and much attention has been focused to unravel the mechanisms and optimize the treatment regimens. Curcumin is an important bioactive component of turmeric that has been widely applied as traditional medicine to prevent and treat various diseases in some countries. Recent studies have demonstrated its potent activities in modulating multiple signaling pathways associated with cellular growth, proliferation, survival, inflammation and oxidative stress. The cardiovascular protective properties of curcumin in CVDs have been fully illustrated in numerous studies. In this review, we first briefly introduce the medicinal history of curcumin. Secondly, we systematically analyze the preclinical studies of curcumin in CVDs such as cardiac hypertrophy, heart failure, drug-induced cardiotoxicity, myocardial infarction, atherosclerosis, abdominal aortic aneurysm, stroke and diabetic cardiovascular complications. The potential molecular targets of curcumin are also summarized. Thirdly, the clinical trials of curcumin in CVDs are overviewed and discussed. Finally, we discuss the therapeutic utility of derivatives of curcumin, and highlight existing problems of curcumin as an effective drug lead in treating CVDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation, Atherosclerosis, and Coronary Artery Disease
Hansson, G. K. (2005) · New England Journal of Medicine · doi:10.1056/nejmra043430 · Cited by 8,773
Bioavailability of curcumin: Problems and promises
Anand, P., Kunnumakkara, A. B., Newman, R. A., & Aggarwal, B. B. (2007) · Molecular Pharmaceutics · doi:10.1021/mp700113r · Cited by 5,543
Heidenreich, P. A., Trogdon, J. G., Khavjou, O. A., Butler, J., Dracup, K., Ezekowitz, M. D., Finkelstein, E. A., Hong, Y., Johnston, S. C., Khera, A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820a55f5 · Cited by 3,208
Doxorubicin: The good, the bad and the ugly effect
Carvalho, C., Santos, R., Cardoso, S., Correia, S., Oliveira, P., Santos, M., & Moreira, P. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788803312 · Cited by 1,509
Cited by
The biology of ergothioneine, an antioxidant nutraceutical
Borodina, I., Kenny, L. C., McCarthy, C. M., Paramasivan, K., Pretorius, E., Roberts, T. J., van der Hoek, S. A., & Kell, D. B. (2020) · Nutrition Research Reviews · doi:10.1017/s0954422419000301 · Cited by 296
Therapeutic applications of curcumin nanomedicine formulations in cystic fibrosis
Quispe, C., Herrera-Bravo, J., Khan, K., Javed, Z., Semwal, P., Painuli, S., Kamiloglu, S., Martorell, M., Calina, D., & Sharifi-Rad, J. (2022) · Progress in Biomaterials · doi:10.1007/s40204-022-00198-3 · Cited by 26
Metadata
- Authors
- Li, H., Sureda, A., Devkota, H. P., Pittalà, V., Barreca, D., Silva, A. S., Tewari, D., Xu, S., & Nabavi, S. M.
- Venue
- Biotechnology Advances
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 38
- Pages
- 107343
- ISSN
- 0734-9750 (ISSN-L)
- OpenAlex
- W2912721012
- Cited by
- 339
- References
- 4
- FWCI
- 12.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
